Zynrelef (bupivacaine/meloxicam ER) / Heron Therapeutics  >>  Phase 3
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zynrelef (bupivacaine/meloxicam ER) / Heron Therapeutics
NCT03974932: Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen

Completed
3b
116
US
HTX-011, Ibuprofen, Acetaminophen, Celecoxib, +/- Bupivacaine HCl, Luer Lock Applicator
Heron Therapeutics
Analgesia
12/20
01/21
NCT03907176: Herniorrhaphy Study for Opioid Elimination

Completed
3b
115
US
HTX-011, Luer lock applicator, Ibuprofen, Acetaminophen
Heron Therapeutics
Analgesia
10/21
11/21
EPOCH 2, NCT03237481 / 2017-001636-19: Phase 3 Herniorrhaphy Study for Postoperative Analgesia

Completed
3
418
Europe, US
HTX-011, Bupivacaine HCl, Saline placebo, Luer-lock applicator, Vial access device
Heron Therapeutics
Postoperative Pain
12/17
01/18
EPOCH 1, NCT03295721: Bunionectomy Study for Postoperative Analgesia

Completed
3
412
US
HTX-011, Saline Placebo, Bupivacaine HCl, Luer-lock applicator, Vial access device
Heron Therapeutics
Postoperative Pain
01/18
03/18
NCT05751421: Pain Relief After PrimaryTKA

Enrolling by invitation
3
60
US
Zynrelef (Bupivacaine 60 MG / Meloxicam 1.8 MG) Per 2.3 ML Extended Release Solution, Bupivacaine HCl 0.5% Injectable Solution, primary total knee replacement
Rothman Institute Orthopaedics
Pain, Postoperative
02/24
02/24

Download Options